Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development.
10.1016/j.apsb.2020.12.011
- Author:
Seyed Hossein KIAIE
1
;
Mohammad Javad SANAEI
2
;
Masoud HESHMATI
2
;
Zahra ASADZADEH
1
;
Iman AZIMI
3
;
Saleh HADIDI
4
;
Reza JAFARI
5
;
Behzad BARADARAN
1
Author Information
1. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz 5173957616, Iran.
2. Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran.
3. School of Pharmacy and Pharmacology, College of Health and Medicine, University of Tasmania, Hobart 7001, Tasmania, Australia.
4. Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran.
5. Solid Tumor Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia 5714783734, Iran.
- Publication Type:Review
- Keywords:
Clinical development;
Immune checkpoint;
Immunotherapy;
Pancreatic cancer;
Tumor microenvironment
- From:
Acta Pharmaceutica Sinica B
2021;11(5):1083-1097
- CountryChina
- Language:English
-
Abstract:
Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.
